Literature DB >> 20440408

[Use and abuse of drugs in cognitive impairment patients].

Galeno Rojas1, Cecilia Serrano, Carol Dillon, Leonardo Bartoloni, Mónica Iturry, Ricardo F Allegri.   

Abstract

INTRODUCTION: Irrational use of drugs for the treatment of cognitive impairment can increase health costs in developing countries.
OBJECTIVE: to analyze the pattern of drug prescription related to the treatment of patients with dementia and to compare them with the income of patients. PATIENTS: 313 community-based outpatients that seeked medical advice for memory problems, in the Memory Center of Zubizarreta General Hospital (Buenos Aires, Argentina), were prospectively assessed during a period of a year.
RESULTS: Patients' mean income was 502.81 "Pesos Argentinos" which is equivalent to US$152 per month (2007). Fourty one point fifty five percent (41.55%) of the patients had dementia, 15.65% psychiatric diseases, 15.01% mild cognitive impairment and 27.79% were normal. Patients received an average of 2.84 drugs/day, 20% of the patients took at least one drug for cognitive impairment (9.85% memantine, 6.38% donepezil and 4% nootropics, cerebral vasodilators or antioxidants), and 39.3% received psychotropic medication (28.11% benzodiazepines and 9.26 % atypical antipsychotics). Twelve point seventy six percent (12.76%) of the patients with mild cognitive impairment were treated with antidementials, 5.74% of normal subjects received antidementials. 4% of patients were exclusively treated with free samples.
CONCLUSION: In our sample irrational degree of using antidemential drugs and psychotropic agents was found.

Entities:  

Mesh:

Year:  2010        PMID: 20440408

Source DB:  PubMed          Journal:  Vertex        ISSN: 0327-6139


  2 in total

1.  A drug utilization study of cognition enhancers in dementia in a tertiary care hospital in mumbai.

Authors:  Karan Thakkar; Shaurya Suman; Gauri Billa
Journal:  J Clin Diagn Res       Date:  2014-05-15

2.  Nutritional status, oxidative stress and dementia: the role of selenium in Alzheimer's disease.

Authors:  Jose R Santos; Auderlan M Gois; Deise M F Mendonça; Marco A M Freire
Journal:  Front Aging Neurosci       Date:  2014-08-28       Impact factor: 5.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.